Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
41.2M
-
Shares change
-
+2.12M
-
Total reported value, excl. options
-
$2.9B
-
Value change
-
+$149M
-
Put/Call ratio
-
1.01
-
Number of buys
-
81
-
Number of sells
-
-76
-
Price
-
$70.31
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2016
202 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2016.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.2M shares
of 96M outstanding shares and own 42.95% of the company stock.
Largest 10 shareholders include FMR LLC (5.88M shares), WELLINGTON MANAGEMENT GROUP LLP (5.26M shares), Capital Research Global Investors (5M shares), VANGUARD GROUP INC (2.83M shares), BlackRock Fund Advisors (1.68M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.67M shares), STATE STREET CORP (1.4M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.18M shares), BlackRock Institutional Trust Company, N.A. (1.05M shares), and Capital International Investors (1M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.